Skip to main content
Top
Published in: Breast Cancer Research 2/2008

01-05-2008 | Poster presentation

Multicentre study of CASP8 polymorphisms in breast cancer

Authors: N Shephard, I Brock, N Camp, L Canon-Albright, B Frank, B Burwinkel, A Cox

Published in: Breast Cancer Research | Special Issue 2/2008

Login to get access

Excerpt

One approach to improve our understanding of the aetiology of breast cancer is to identify the genes involved in inherited susceptibility. These range from the rare high-penetrance mutations of the BRCA1 and BRCA2 genes to common low-penetrance variants, which are just beginning to be identified by means of whole-genome and candidate gene association studies. Owing to their small effect, these common variants are difficult to identify, requiring studies with large sample sizes. The Breast Cancer Association Consortium recently identified a single nucleotide polymorphism (SNP) in the CASP8 gene that is associated with a reduction in risk of breast cancer (rs1045485; D302H; P trend = 1.1 × 10-7) in a large multicentre cohort [1]. …
Literature
1.
go back to reference Cox A, Dunning AM, Garcia-Closas M, et al: A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet. 2007, 39: 352-358. 10.1038/ng1981.CrossRefPubMed Cox A, Dunning AM, Garcia-Closas M, et al: A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet. 2007, 39: 352-358. 10.1038/ng1981.CrossRefPubMed
Metadata
Title
Multicentre study of CASP8 polymorphisms in breast cancer
Authors
N Shephard
I Brock
N Camp
L Canon-Albright
B Frank
B Burwinkel
A Cox
Publication date
01-05-2008
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2008
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1935

Other articles of this Special Issue 2/2008

Breast Cancer Research 2/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine